Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy.
about
Lipoprotein(a) in cardiovascular diseasesBiological and Nutritional Properties of Palm Oil and Palmitic Acid: Effects on HealthRosuvastatin Treatment for Preventing Contrast-Induced Acute Kidney Injury After Cardiac Catheterization: A Meta-Analysis of Randomized Controlled TrialsAtherosclerosis: process, indicators, risk factors and new hopesNonalcoholic fatty liver disease and vascular disease: state-of-the-art.Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosisCocoa, hazelnuts, sterols and soluble fiber cream reduces lipids and inflammation biomarkers in hypertensive patients: a randomized controlled trialA review of plant-based compounds and medicinal plants effective on atherosclerosis.Association of the apolipoprotein b/apolipoprotein a-I ratio, metabolic syndrome components, total cholesterol, and low-density lipoprotein cholesterol with insulin resistance in the population of georgia.Effects of R219K polymorphism of ATP-binding cassette transporter 1 gene on serum lipids ratios induced by a high-carbohydrate and low-fat diet in healthy youthSerum adipokine and inflammatory markers before and after liver transplantation in recipients with major cardiovascular eventsPrediction of risk factors for coronary heart disease using Framingham Risk Score in Korean men.Comparison of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patient with chronic kidney disease undergoing percutaneous coronary intervention.Thyroid hormones and thyroid hormone receptors: effects of thyromimetics on reverse cholesterol transport.Risk of cardiovascular disease in a traditional African population with a high infectious load: a population-based studyEffect of aerobic exercise on risk factors of cardiovascular disease and the apolipoprotein B / apolipoprotein a-1 ratio in obese woman.Apolipoprotein B is highly associated with the risk of coronary heart disease as estimated by the Framingham risk score in healthy Korean men.Analysis of human blood plasma proteome from ten healthy volunteers from Indian populationAssociations between smoking, components of metabolic syndrome and lipoprotein particle size.The apolipoprotein B/apolipoprotein A-I ratio as a potential marker of plasma atherogenicity.Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease.Bone Mineral Changes and Cardiovascular Effects among Female Athletes with Chronic Menstrual DysfunctionTamoxifen alters the plasma concentration of molecules associated with cardiovascular risk in women with breast cancer undergoing chemotherapyCausal Role of Alcohol Consumption in an Improved Lipid Profile: The Atherosclerosis Risk in Communities (ARIC) Study.Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis.Clinical use and pathogenetic basis of laboratory tests for the evaluation of primary arterial hypertension.Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease.Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies.The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence.Apolipoproteins A-I, B, and C-III in young adult Cherokee with metabolic syndrome with or without type 2 diabetes.Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview.ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity.Association between Osteocalcin, Metabolic Syndrome, and Cardiovascular Risk Factors: Role of Total and Undercarboxylated Osteocalcin in Patients with Type 2 DiabetesBlood Triglycerides Levels and Dietary Carbohydrate Indices in Healthy Koreans.Effects of L-carnitine supplementation on lipid profiles in patients with coronary artery diseaseA clinical study of serum lipid disturbance in Chinese patients with sudden deafness.The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment.A study of serum apolipoprotein A1, apolipoprotein B and lipid profile in stroke.Age and follow-up time affect the prognostic value of the ECG and conventional cardiovascular risk factors for stroke in adult menComparison of Apolipoprotein Concentrations and Values of APOB:APOAI with Traditional Lipid Measures in Women Diagnosed with Acute Cornonary Syndromes - A Preliminary Report.
P2860
Q21284797-A99FD726-0285-449A-8BE1-5A625713467DQ26782354-27E9F428-B036-417E-9ADA-5FD1DC85DDBCQ26801795-FA196D43-8EFD-4216-9F4B-D735E074AF40Q26822655-F19D958B-2F62-4D04-9AB6-E57FC090E3A2Q27692035-36F9054D-E964-4E99-8886-4D3D296B2B91Q28278173-A0CF7B77-02C2-409B-858C-E4E7AD5FB045Q28731712-637BCED5-6511-4A92-B5B2-3C06F8951BDEQ33561027-F5CD53DF-DB93-4401-ACEF-88602D4DA13AQ33739964-D0D11A3B-765C-4E84-9449-D394400CB4E2Q33766338-FD191D1C-D752-41F3-9EF1-9D63DA6553D9Q33812634-F6BA98D5-3CBD-4B64-9CEC-3F919862E6D8Q34427908-6DFAD3CE-B76D-4033-86E1-52F01748904DQ34428322-E2DFF715-AB0C-491D-8F29-200F83C601BBQ34428756-06C44E76-D273-45DB-B550-D71F6030E32CQ34447546-C089411F-20E9-48C5-AFE3-A3AB4F939B0DQ34567313-606C5E86-69FA-448B-9BF0-B0844B9D03ABQ34853434-23F89741-A08E-43C7-A416-DB9C38195067Q34973952-695974D2-A236-4354-AA42-C5C54529C666Q35042556-6D8B3979-BAE9-4464-8448-FC1A020F4414Q35234169-E7D3F56E-4B45-4B3A-BDF9-E188DEAA119BQ35602513-D4F325B0-2A78-452D-940E-729D1F6CF818Q35840513-740A13B5-8FD1-4AD4-821D-79FAE2514254Q35913219-197FF6ED-2569-4CF6-8D38-D2BDFE7CD5CEQ35915957-D65F44B9-261D-4A80-86E6-973DFD1B9706Q35954510-93756DA9-1700-4CAE-91DD-3D8C03A34F9DQ36359500-1E86437A-A5E9-4EB2-9B1E-B24694D187B9Q36455894-F22823C4-1234-4B37-A8AE-544E72956938Q36455898-40F90C6F-59E0-4AED-ABFD-82A4B088B73BQ36455901-0877A7B3-F51D-4520-9E30-2242C6AFB76BQ36573819-C14F46AC-54B0-438B-B19E-EF4C21053CDFQ36653658-C7B17A7D-4B39-4115-AEA1-3C17D5DD7125Q36683234-EED71013-45E9-4985-82AE-A44B7DE310E1Q36801946-738A3A17-C425-4410-8834-B3C8BE393AF8Q36983411-AC20E7C6-4493-4265-BE5D-9073ECB6EB4BQ37018050-A755C34B-69BD-48D5-88F7-C7436BB0D314Q37028501-77352647-144C-43C4-9A42-EFE7C625D535Q37107485-8DDE9CE9-AC4A-43EC-ABFF-706ABA12761FQ37111281-38B3C59F-CACA-4CA4-BA83-BBC36A624958Q37121372-B337984B-D2C1-4DAF-AB03-38B2BAEF9F43Q37155363-B15E32E3-A6A8-4310-A4CD-753F66AFA40E
P2860
Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Apolipoprotein B and apolipopr ...... s for lipid-modifying therapy.
@ast
Apolipoprotein B and apolipopr ...... s for lipid-modifying therapy.
@en
type
label
Apolipoprotein B and apolipopr ...... s for lipid-modifying therapy.
@ast
Apolipoprotein B and apolipopr ...... s for lipid-modifying therapy.
@en
prefLabel
Apolipoprotein B and apolipopr ...... s for lipid-modifying therapy.
@ast
Apolipoprotein B and apolipopr ...... s for lipid-modifying therapy.
@en
P2860
P1476
Apolipoprotein B and apolipopr ...... s for lipid-modifying therapy.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2796.2003.01276.X
P407
P577
2004-02-01T00:00:00Z